| 1. |
Oliveira LB, Reis PA. Silicone oil tamponade in 23 gauge transconjunctival sutureless vitrectomy[J]. Retina, 2007, 27(8):1054-1058.
|
| 2. |
Riemann CD, Miller DM, Foster RE, et al. Outcomes of transconjunctival sutureless 25-gauge vitrectomy with silicone oil infusion[J].Retina, 2007, 27(3):296-303.
|
| 3. |
Castellarin A, Grigorian R, Bhagat N, et al. Vitrectomy with silicone oil infusion in severe diabetic retinopathy[J]. Br J Ophthalmol, 2003, 87(3):318-321.
|
| 4. |
Barzideh N, Johnson TM. Subfoveal fluid resolves slowly after pars plana vitrectomy for tractional retinal detachment secondary to proliferative diabetic retinopathy[J]. Retina, 2007, 27(6):740-743.
|
| 5. |
Schatz B, El-Shabrawi Y, Haas A, et al. Adverse side effects with perfluorohexyloctane as a long term tamponade agent in complicated vitreoretinal surgery[J]. Retina, 2004,24(4):567-573.
|
| 6. |
Altan T, Acar N, Kapran Z, et al. Transconjunctival 25-gauge sutureless vitrectomy and silicone oil injection in diabetic tractional retinal detachment[J]. Retina, 2008, 28(9):1201-1206. DOI:10.1097/IAE.0b013e3181853d3c.
|
| 7. |
Ghasemi Falavarjani K, Modarres M, Hadavandkhani A, et al. Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy[J]. Eye, 2015,29(9):1199-1203. DOI:10.1038/eye.2015.114.
|
| 8. |
Meredith TA, Kaplan HJ, Aaberg TM. Pars plana vitrectomy techniques for relief of epiretinal traction by membrane segmentation[J]. Am J Ophthalmol, 1980, 89(3):408-413.
|
| 9. |
Rice TA, Michels RG, Rice EF. Vitrectomy for diabetic traction retinal detachment involving the macula[J]. Am J Ophthalmol, 1983, 95(1):22-33.
|
| 10. |
Thompson JT, de Bustros S, Michels RG, et al. Results and prognostic factors in vitrectomy for diabetic vitreous hemorrhage[J]. Arch Ophthalmol, 1987, 105(2):191-195.
|
| 11. |
Williams DF, Williams GA, Hartz A, et al. Results of vitrectomy for diabetic traction retinal detachments using the en bloc excision technique[J]. Ophthalmology, 1989, 96(6):752-758.
|
| 12. |
Qamar RM, Saleem MI, Saleem MF. The outcomes of pars plana vitrectomy without endotamponade for tractional retinal detachment secondary to proliferative diabetic retinopathy[J]. Int J Ophthalmol, 2013, 6(5):671-674. DOI:10.3980/j.issn.2222-3959.2013.05.23.
|
| 13. |
Newman DK. Surgical management of the late complications of proliferative diabetic retinopathy[J]. Eye, 2010, 24(3):441-449. DOI:10.1038/eye.2009.325.
|
| 14. |
Sternfeld A, Axer-Siegel R, Stiebel-Kalish H, et al. Advantages of diabetic tractional retinal detachment repair[J]. Clin Ophthalmol, 2015, 9:1989-1994. DOI:10.2147/OPTH.S90577.
|
| 15. |
Yeh PT, Yang CM, Yang CH. Distribution, reabsorption, and complications of preretinal blood under silicone oil after vitrectomy for severe proliferative diabetic retinopathy[J]. Eye, 2012, 26(4):601-608. DOI:10.1038/eye.2011.318.
|
| 16. |
di Lauro R, De Ruggiero P, di Lauro R,et al. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy[J]. Graefe´s Arch Clin Exp Ophthalmol, 2010, 248(6):785-791. DOI:10.1007/s00417-010-1303-3.
|
| 17. |
Hattori T, Shimada H, Nakashizuka H, et al. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy[J]. Retina, 2010, 30(5):761-764. DOI:10.1097/IAE.0b013e3181c70168.
|
| 18. |
Osaadon P, Fagan XJ, Lifshitz T, et al. A review of anti-VEGF agents for proliferative diabetic retinopathy[J]. Eye, 2014, 28(5):510-520. DOI:10.1038/eye.2014.13.
|
| 19. |
Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev, 2015, 8:CD008214. http://dx.doi.org/10.1002/14651858.CD008214.pub3.DOI:10.1002/14651858.CD008214.pub3.
|
